Your session is about to expire
← Back to Search
MK-8189 for Schizophrenia
This trial is testing a new drug for safety and how well it is tolerated by people with schizophrenia.
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Side effects dataFrom 2018 Phase 2 trial • 224 Patients • NCT03055338
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
How many participants are involved in this experiment?
"Indeed, according to clinicaltrials.gov the medical trial is currently inviting participants; it was first posted on July 12th 2022 and most recently modified on November 16th of that year. This study needs 54 volunteers recruited from three different sites."
What qualifications must a person meet in order to join this experiment?
"This medical study is accepting 54 candidates aged between 18 and 55 with a diagnosis of schizophrenia. The main criteria for inclusion in this experiment includes: [list the criteria here]."
Has the FDA endorsed MK-8189 for public usage?
"With limited efficacy and safety data, MK-8189 received a score of 1 on the Power scale."
Is this research open to septuagenarians?
"This medical research is enrolling participants aged 18-55 years old."
Is this research currently accepting volunteers?
"Affirmative. The clinical trial is actively looking for participants, as indicated by the information hosted on clinicaltrials.gov. This medical study was initially posted on July 12th 2022 and its details were updated most recently on November 16th 2022. Approximately 54 patients need to be recruited at 3 separate sites."
Share this study with friends